Elinzanant Significantly Reduces Hot Flashes in Clinical Trial

A new study indicates that elinzanant, a neurokinin 3 (NK3) receptor antagonist, substantially reduces the frequency of hot flashes experienced by women going through menopause. The findings, published in The New England Journal of Medicine, offer a potential new treatment option for a common and often debilitating symptom of menopause.

Study Design and Participants

The Phase 3 clinical trial involved 352 women experiencing moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes. Participants were randomly assigned to one of two groups:

• Elinzanant Group (n=316): Received the active drug, elinzanant, for 52 weeks.
• Placebo Group (n=158): Received a placebo for the first 12 weeks, followed by elinzanant for the remaining 40 weeks.

The average age of participants was 54.6 years, and they reported an average of 11.4 hot flashes per day at the beginning of the study.

Elinzanant’s Impact on Hot Flash Frequency

The results demonstrated a significant reduction in hot flash frequency with elinzanant treatment. Participants taking elinzanant experienced an average decrease of 7.8 hot flashes per day. In contrast, the placebo group experienced a reduction of only 3.4 hot flashes per day. This difference was statistically significant, indicating that elinzanant is more effective than placebo in managing hot flashes.

Understanding NK3 Receptor Antagonists

Elinzanant works by blocking the action of neurokinin B (NKB), a neurotransmitter that plays a key role in regulating body temperature. During menopause, declining estrogen levels can lead to increased NKB activity, triggering hot flashes. By blocking the NK3 receptor, elinzanant helps to restore temperature regulation and reduce the frequency of these episodes. EndocrineWeb provides further details on the mechanism of action.

Safety and Side Effects

Importantly,the study authors reported that the side effect profiles were similar between the elinzanant and placebo groups. This suggests that elinzanant is generally well-tolerated. Common side effects reported in the trial included headache, nausea, and fatigue, but these were generally mild to moderate in severity.

Key Takeaways

• Elinzanant significantly reduces the frequency of hot flashes in women experiencing menopause.
• The drug targets the NK3 receptor, offering a novel mechanism for managing vasomotor symptoms.
• Elinzanant appears to be well-tolerated, with a similar side effect profile to placebo.

Future Outlook

These findings represent a significant step forward in the treatment of menopausal hot flashes. Elinzanant is currently under review by the Food and Drug Management (FDA), and if approved, could provide a much-needed new option for the millions of women who experience this challenging symptom. Further research will continue to evaluate the long-term effects and optimal use of elinzanant.

Publication Date: 2025/08/26 11:51:07